Search results
Results From The WOW.Com Content Network
Gilead Sciences (NASDAQ: GILD) Q2 2024 Earnings Call Aug 08, 2024, 4:30 p.m. ET. ... I'll now hand the call over to Jacquie Ross, vice president of investor relations and corporate strategic finance.
For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but raised its adjusted profit estimate to $3.60 to $3.90 a share from a previous $3.45 to $3.85 a ...
Gilead Sciences. Gilead Sciences, Inc. ( / ˈɡɪliəd /) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
April 25, 2024 at 4:11 PM. By Deena Beasley. (Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug ...
Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
(Reuters) -Drugmaker Gilead Sciences on Tuesday said its third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes. Wall Street analysts had ...
John F. Milligan is an American former executive who was the CEO of Gilead Sciences, a biotechnology company based in the United States from March 2016. He was previously appointed President of the company and had maintained that role since May 2008. [1] He held various other positions during his tenure with Gilead including COO and CFO and ...